| Q35010158 | Antibody and T cell responses in reciprocal prime-boost studies with full-length and truncated merozoite surface protein 1-42 vaccines |
| Q48035058 | Antigenicity and immunogenicity of the N-terminal 33-kDa processing fragment of the Plasmodium falciparum merozoite surface protein 1, MSP1: implications for vaccine development |
| Q35456892 | Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodies |
| Q27972548 | Expression and biochemical characterization of the Plasmodium falciparum DNA repair enzyme, flap endonuclease-1 (PfFEN-1) |
| Q36938795 | Heterologous expression of plasmodial proteins for structural studies and functional annotation |
| Q53191042 | Identification of Ehrlichia ruminantium proteins that activate cellular immune responses using a reverse vaccinology strategy. |
| Q47834462 | Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling |
| Q47427480 | In vitro and in vivo evaluation of five low molecular weight proteins of Ehrlichia ruminantium as potential vaccine components. |
| Q34367020 | Insect cells are superior to Escherichia coli in producing malaria proteins inducing IgG targeting PfEMP1 on infected erythrocytes |
| Q36615170 | Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine |
| Q39085988 | Plasmodium falciparum anti-MSP1-19 antibodies induced by MSP1-42 and MSP1-19 based vaccines differed in specificity and parasite growth inhibition in terms of recognition of conserved versus variant epitopes |
| Q28740432 | T cell epitope regions of the P. falciparum MSP1-33 critically influence immune responses and in vitro efficacy of MSP1-42 vaccines |